A new smart wound dressing technology has shown significant promise in preclinical trials. This innovative dressing releases antibiotics only when harmful bacteria are detected, addressing the growing concern of antimicrobial resistance.
Traditional wound care often exposes tissues to suboptimal drug levels, which can lead to resistance and infection recurrence. Researchers have developed a hydrogel that incorporates a cephalosporin-derived β-lactamase cleavable crosslinker. This hydrogel degrades in the presence of bacterial enzymes, releasing ciprofloxacin-loaded liposomes.
In ex vivo and in vivo models, the dressing was highly effective against Pseudomonas aeruginosa infections. A single application achieved complete bacterial eradication and enhanced wound healing, surpassing a commercial silver-based hydrogel dressing. Importantly, the material did not induce ciprofloxacin resistance in non-β-lactamase-producing bacteria.
This targeted approach could revolutionize wound care by delivering antibiotics precisely where needed, reducing unnecessary exposure, and limiting resistance development. Further clinical evaluation is necessary to ensure safety and efficacy.